Skip to main content

TIDEWATER

tidewaternews-logo
SUBSCRIBE
Menu
Menu
tidewaternews-logo
Subscribe
Menu

Archives

Brian Rowan’s Role: VP of Sales Accused of Steering a Nationwide Kickback Machine

Brian Rowan’s Role: VP of Sales Accused of Steering a Nationwide Kickback Machine

Authorities say Rowan used his executive position to induce allograft purchases, inflate insurance reimbursements, conceal illegal rebates and bribes, and convert a nationwide sales organization into an alleged healthcare fraud network that generated hundreds of millions of dollars. PHOENIX, Arizona — Brian Rowan, a former vice president of sales for an amniotic wound-allograft company, allegedly used his senior commercial position to steer a nationwide kickback operation that submitted approximately $1.2 billion in fraudulent healthcare claims and collected about $614 million. Federal prosecutors portray Rowan as more than an executive who benefited from misconduct committed elsewhere, alleging instead that he helped direct the sales incentives, inflated invoices, hidden rebates, pass-through payments, and purchasing relationships that allowed the disputed reimbursements to expand across the United States. Rowan, a 47-year-old Las Vegas resident, has been charged with conspiracy to commit healthcare and wire fraud, healthcare fraud, conspiracy to defraud the United States and pay healthcare kickbacks, paying healthcare kickbacks, and transactional money laundering. Those charges remain allegations because Rowan has not been convicted, retains the constitutional presumption of innocence, and may challenge the government’s evidence throughout proceedings requiring prosecutors to prove every element of each charged offense beyond a reasonable doubt. A Vice President Positioned Near the Commercial Center As vice president of sales, Rowan allegedly occupied a position capable of influencing representatives, provider relationships, product purchasing, revenue targets, compensation arrangements, invoice practices, and the broader commercial strategy responsible for placing expensive wound products into reimbursable medical settings. Sales executives generally do not select treatments for individual patients, but they can shape the financial environment surrounding those decisions by establishing commission structures, approving discounts, directing representatives, rewarding exceptional utilization, and determining which providers receive sustained commercial attention. The government’s case therefore focuses upon whether Rowan knowingly used those ordinary executive powers for an unlawful purpose, transforming legitimate sales management into an alleged mechanism for inducing purchases, corrupting medical decisions, and extracting inflated payments from healthcare benefit programs. According to the Justice Department’s official description of the Brian Rowan prosecution, Rowan and his alleged co-conspirators caused approximately $1.2 billion in claims to reach Medicare, TRICARE, CHAMPVA, commercial insurers, and other benefit programs between December 2021 and June 2024. Approximately $614 million was paid upon those claims, meaning the alleged operation converted sales pressure, allograft purchases, provider applications, disputed medical documentation, inflated invoices, and concealed remuneration into an extraordinary stream of public and private insurance money. Sales Leadership Allegedly Powered the Network Federal prosecutors allege that Rowan helped cause hundreds of millions of dollars in kickbacks, bribes, and rebates to reach providers and sales representatives, creating powerful financial incentives for continued purchasing and application of the company’s expensive wound allografts. The alleged arrangement rewarded several levels of the network simultaneously because providers could receive undisclosed profits, representatives could earn sales compensation, the company could expand revenue, and Rowan could increase his personal earnings whenever additional reimbursable products moved through the system. This interconnected compensation structure allegedly gave Rowan’s sales organization the characteristics of a self-reinforcing machine, with every successful reimbursement producing financial rewards that encouraged representatives and providers to identify more patients, purchase more products, and submit additional claims. A lawful sales executive can enthusiastically promote clinically appropriate products, although federal law draws important boundaries when compensation induces federally reimbursable purchases, undisclosed rebates alter reported costs, or commercial representatives influence medical decisions that should remain independent. Prosecutors contend that Rowan crossed those boundaries by helping create and sustain financial arrangements under which providers allegedly profited from product selection while insurers received misleading information concerning acquisition costs, discounts, medical necessity, and the true economic substance of transactions. High Reimbursements Created the Alleged Opportunity Amniotic wound allografts can provide legitimate benefits for appropriately selected patients with difficult wounds, particularly when conventional treatment has failed, but their substantial prices and complicated reimbursement requirements can also generate unusually profitable opportunities for exploitation. The financial risk increases when products are acquired at one economic price, represented in paperwork at a substantially higher price, and reimbursed according to figures that fail to disclose rebates, credits, commissions, returned funds, or other benefits that reduce the purchaser’s genuine expense. Rowan’s alleged sales network reportedly operated within this vulnerable space, encouraging providers to purchase and apply expensive allografts while concealing financial inducements capable of influencing both the clinical decision and the reimbursement requested from government programs. Because each additional graft could produce significant revenue, prosecutors allege that sales representatives and providers possessed incentives to expand wound dimensions, application frequency, product quantities, or patient eligibility beyond what legitimate medical circumstances and coverage requirements supported. The government will need to prove that Rowan understood how those incentives affected treatment and billing, rather than merely leading a commercially successful organization whose independent providers or lower-level employees violated rules without his knowledge or authorization. Kickbacks Allegedly Corrupted Purchasing Decisions The federal Anti-Kickback Statute generally protects healthcare programs from arrangements in which remuneration is offered or paid to induce or reward referrals, purchases, recommendations, or orders involving items and services reimbursable through covered federal programs. These restrictions recognize that concealed payments can alter professional judgment without appearing upon a patient’s medical record, allowing financial interests to influence treatments while patients and insurers mistakenly assume that clinical necessity alone determined the recommendation. Prosecutors allege that Rowan used his sales authority to support precisely this corruption, helping direct financial benefits toward providers whose purchasing and treatment decisions generated substantial allograft revenue throughout the alleged nationwide operation. The alleged kickbacks did not merely reduce honest market competition because they reportedly encouraged medically unreasonable or unnecessary procedures, exposing vulnerable patients to treatment selected partly for the reimbursement and profit available to commercial participants. When a provider earns more by selecting a particular expensive product, applying larger quantities, or repeating procedures, even seemingly legitimate sales support can become evidence of inducement if compensation depends upon utilization and remains hidden from insurers. Sham Invoices Allegedly Inflated Reimbursements Federal prosecutors contend that Rowan and his alleged co-conspirators issued sham sales invoices displaying amounts greater than the

H.I.G. Capital Signs Definitive Agreement to Acquire TERRAS

LONDON, July 6, 2026 /PRNewswire/ — H.I.G. Capital (“H.I.G.”), a leading global alternative investment firm with $75 billion of capital under management, is pleased to announce that one of its affiliates has entered into a definitive agreement to…

Ascletis Submits Two IND Applications to the U.S. FDA for the Treatment of Obesity: ASC36 Once-Monthly Injection, a Peptide Amylin Receptor Agonist, and ASC36_35 FDC Once-Monthly Injection, a Co-Formulation of ASC36 Plus Peptide GLP-1R/GIPR Agonist ASC35

ASC36_35 FDC, a once-monthly subcutaneous (SQ) injection co-formulation of ASC36 and ASC35, is a potentially first-in-class drug candidate targeting three validated targets of amylin receptor, GLP-1R and GIPR.ASC36_35 FDC demonstrated approximately 51% greater relative body weight reduction compared…